• Atara Biotherapeutics received a Nasdaq notice on April 30, 2026 for failing to meet $50 million minimum market value of listed securities requirement for Nasdaq Global Select Market.
• Nasdaq granted a 180-day compliance period through Oct. 27, 2026.
• Compliance requires market value of listed securities to close at or above $50 million for at least 10 consecutive business days.
• Common stock continues to trade on Nasdaq Global Select Market under symbol ATRA while company works to regain compliance.
• Atara may seek transfer to Nasdaq Capital Market; failure to regain compliance by deadline would trigger a delisting notice with appeal rights.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atara Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-201397), on May 01, 2026, and is solely responsible for the information contained therein.